<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002455</url>
  </required_header>
  <id_info>
    <org_study_id>ARG-CO/BR-1</org_study_id>
    <secondary_id>CDR0000072435</secondary_id>
    <nct_id>NCT00002455</nct_id>
  </id_info>
  <brief_title>Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma</brief_title>
  <official_title>Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Oncologico de Excelencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer
      cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in
      treating patients who have had surgery for breast cancer, colon cancer, or melanoma.

      PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as
      maintenance immunotherapy following surgery in treating patients with breast cancer, colon
      cancer, or melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the survival of patients with colon cancer, breast cancer, or melanoma with
           minimal residual disease after surgical resection treated with maintenance immunotherapy
           using Corynebacterium granulosum P40.

        -  Determine leucocyte adherence inhibition, an indication of metastases, over time in
           patients treated with this regimen.

      OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with
      case-controls by disease type and stage.

      Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40
      subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for
      life.

      Patients are followed for survival.

      PROJECTED ACCRUAL: Not specified
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1971</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to study parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate</measure>
  </primary_outcome>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Corynebacterium granulosum P40</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of colon cancer, breast cancer, or melanoma with minimal residual disease
             (at least 90% of tumor mass resected) after surgical resection

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  20 to 80

        Sex:

          -  Not specified

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Omar De Carli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Oncologico de Excelencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico de Excelencia</name>
      <address>
        <city>Gonnet</city>
        <state>Buenos Aires</state>
        <zip>1987 MB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>De Carli HO: Immunostimulation and follow-up in long term subclinical cancer. Buenos Aires. Argentina: Centro Oncologico de Excelencia.</citation>
  </reference>
  <verification_date>November 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage I melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

